Respirology

Top Medical News
SBRT on par with HART in limited-stage small cell lung cancer
Yesterday
Stereotactic body radiotherapy (SBRT) is a safe and effective alternative to hyperfractionated accelerated radiotherapy (HART) in the treatment of limited-stage small-cell lung cancer (LS-SCLC), suggests a recent study.
Bacterial codetection tied to better outcomes in ventilated infants with bronchiolitis
Stephen Padilla, 5 days ago
Bacterial respiratory tract infection normally occurs in infants requiring early intubation in the emergency department (ED) for viral bronchiolitis, according to a study. However, respiratory bacterial codetection appears to shorten the duration of mechanical ventilation (MV) and length of stay (LOS) of these patients in the intensive care unit (ICU).
HK data validate cerebrovascular safety of BNT162b2, CoronaVac vaccines
Audrey Abella, 19 Feb 2024
A Hong Kong study finds no association between the BNT162b2 and CoronaVac vaccines and subclinical progression of MRI cerebrovascular disease biomarkers in community-dwelling adults.
LIPI predicts survival of IPF patients
15 Feb 2024
Use of the lung immune prognostic index (LIPI) can predict the survival of patients with idiopathic pulmonary fibrosis (IPF) and may even help in IPF management, suggests a recent study.
What are the features of small airway disease in AAV?
14 Feb 2024
One unique indicator of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-related lung involvement is small airway disease (SAD), which has distinct clinical features, reports a study.
Mupirocin proves safety as prevention for catheter-related infections
Stephen Padilla, 14 Feb 2024
Use of topical mupirocin prophylaxis is feasible and has an acceptable safety profile for the long-term prevention of indwelling pleural catheter (IPC)- or indwelling peritoneal catheter (IPeC)-related infections, results of a pilot study have shown.
COVID-19 associated with increased BPH complications and deterioration
Christina Lau, 14 Feb 2024

SARS-CoV-2 infection is associated with significantly higher incidence of benign prostatic hyperplasia (BPH) complications and addition of 5-alpha reductase inhibitor (5ARI) for combination therapy in male patients with lower urinary tract symptoms (LUTS) on alpha-1 adrenoreceptor blocker (AARB) monotherapy, a territory-wide retrospective cohort study in Hong Kong has shown.

Special Reports
COVID-19, influenza, death, hospital admission, adverse outcome
07 Feb 2024
A comparative analysis has shown that COVID-19 is distinctly more severe than seasonal influenza, with significantly increased long-term risks of adverse health outcomes and burdens.1
Nicorette® QuickMist Launch Symposium
19 Jan 2024
During the launch of Nicorette® QuickMist at the Kuala Lumpur Nicotine Addiction International Conference (KLNAC) 2023, a panel of distinguished experts led the discussion on the role of Nicotine Replacement Therapy (NRT) on smoking cessation management. The panel comprised of notable experts, including Professor Chris Bullen (New Zealand), Associate Professor Dr Amer Siddiq bin Amer Nordin (Malaysia), Dr Philip Tønnesen (Denmark) and Professor Philip Eng (Singapore).
Real-World Effectiveness of COVID-19 mRNA Vaccines in Patients with Immune-Mediated Inflammatory Diseases (IMID)
14 Dec 2023
Patients with immune-mediated inflammatory diseases face increased COVID-19 risks, but mRNA vaccines offer crucial protection against severe outcomes, including hospitalisation and death, as highlighted by real-world data.
A closer look at ceftazidime-avibactam in real-world settings
07 Nov 2023

Antibiotic misuse and overuse fuel mutations in bacteria, leading to drug-resistant “superbugs,” with terrifying aftermath. Without intervention, antimicrobial resistance could cause 10 million deaths annually by 2050.

Every year, from November 18–24, the World Antimicrobial Awareness Week highlights these risks and promotes innovative treatments, enhanced surveillance, and best-practice sharing among clinicians. This article offers insights on the use of the fixed-dose combination antibiotic ceftazidime-avibactam in daily hospital settings.

Comparative Effectiveness of mRNA COVID-19 Vaccines in the Immunocompromised Population: A Systematic Review & Meta-Analysis
01 Nov 2023
The US Centers for Disease Control and Prevention and the Ministry of Health Singapore recommend a third dose of mRNA-1273 or BNT162b2 COVID-19 vaccine as a part of the primary vaccination course in individuals with moderate to severe immunocompromised (IC) conditions. A recent systematic literature review and pairwise meta-analysis comparing the clinical effectiveness of mRNA-1273 versus BNT162b2 in IC individuals found that mRNA-1273 is associated with better clinical outcomes compared with BNT162b2 in the vulnerable IC populations.
Real-world insights on comparative effectiveness of mRNA COVID-19 boosters
03 Oct 2023

Two target trials were emulated to compare the effectiveness of third doses of mRNA-based COVID-19 vaccines among US veteran population and across at-risk US veteran populations.

Product Highlight - VAXIGRIP TETRA
12 Sep 2023
Inactivated quadrivalent influenza vaccine (split virion) 0.5 mL suspension for injection
Conference Reports
AHA to cardiothoracic surgeons: Get more involved in PE care
Elvira Manzano, 04 Feb 2024
A scientific statement endorsed by the American Heart Association (AHA) has urged cardiothoracic surgeons to get more involved in the care of patients at high risk for pulmonary embolism (PE) – and to do it much earlier – to improve outcomes.
Cardiac surgery outcomes worsen during COVID
Elvira Manzano, 03 Feb 2024
Heart surgery during the COVID-19 pandemic took a turn for the worse, with higher cost and poorer survival regardless of people’s socioeconomic status, according to US data.
Oesophageal cancer survivors more prone to late-onset pneumonia
Audrey Abella, 18 Jan 2024
Oesophageal cancer survivors are more likely to develop late-onset pneumonia during their clinical course, a study suggests.
Adjuvant alectinib benefits Asians with resected ALK+ NSCLC
Elvira Manzano, 09 Jan 2024
Adjuvant treatment with alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) better than platinum-based chemotherapy at 2 years in Asian patients with early-stage, completely resected ALK-positive non–small cell lung cancer (ALK+ NSCLC) in an exploratory analysis of the phase III ALINA trial.
Mobocertinib only as good as platinum chemo in first-line NSCLC treatment
Jairia Dela Cruz, 20 Dec 2023
In the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) patients with EGFR exon 20 insertion (ex20ins) mutations, the investigational mobocertinib is safe and efficacious but not necessarily better than platinum-based chemotherapy, according to the phase III EXCLAIM-2 trial.
Amivantamab-based regimens may alter EGFR-mutant NSCLC treatment paradigm in Asia
Audrey Abella, 11 Dec 2023
Updates from two MARIPOSA trials presented at ESMO Asia 2023 underpin the potential of amivantamab-based regimens for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (EGFRm NSCLC) in Asian subgroups.
Expert shares lessons from COVID-19
Elvira Manzano, 06 Dec 2023
The world is out of the pandemic, but several subvariants of Omicron are still evolving, says Dr Adrian Chan, respiratory physician and intensivist at Mount Elizabeth Novena Hospital, Singapore, during his talk at APSR 2023.